For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
125 - 370 mg per m² of body surface area (BSA)
From 125 To 370 mg per m² of body surface area (BSA) once every day
The recommended dose ranges from 125 mg/m²/day (3.38 mg/kg/day) to 300 mg/m²/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m² (24.32 mg/kg), during the time of the entire conditioning treatment.
The recommended dose in lymphoma is 370 mg/m²/day (10 mg/kg/day) divided in two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m² (10 mg/kg), during the time of the entire conditioning treatment.
Thiotepa must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.
Intravenous
3.38 - 10 mg per kg of body weight
From 3.38 To 10 mg per kg of body weight once every day
The recommended dose ranges from 125 mg/m²/day (3.38 mg/kg/day) to 300 mg/m²/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m² (24.32 mg/kg), during the time of the entire conditioning treatment.
The recommended dose in lymphoma is 370 mg/m²/day (10 mg/kg/day) divided in two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m² (10 mg/kg), during the time of the entire conditioning treatment.
Thiotepa must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.